Drug interactions among the antiretrovirals
Current Infectious Disease Reports, ISSN: 1523-3847, Vol: 6, Issue: 2, Page: 159-162
2004
- 17Citations
- 12Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations17
- Citation Indexes17
- 17
- CrossRef13
- Captures12
- Readers12
- 12
Review Description
There are 20 antiretroviral agents approved by the US Food and Drug Administration (FDA), four of which were approved in 2003. With 20 antiretrovirals FDA-approved, interactions occur when the medications alter the toxicity profile or efficacy of the other medication. In order to maintain clinical relevance, only the most significant interactions published within the past 12 months are highlighted in this article. Interactions discussed involve atazanavir, fosamprenavir, lopinavir/ritonavir, tenofovir, proton pump inhibitors, H-blockers, clarithromycin, and vardenafil. Important interaction-management strategies also are discussed. The field of HIV pharmacology is constantly advancing, as are the drug interaction data. To screen, manage, dose adjust, and counsel, the physician and other health care professionals are highly advised and encouraged to consult with an infectious disease clinical pharmacist when managing patients receiving highly active antiretroviral therapy. Copyright © 2004 by Current Science Inc.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=3142764628&origin=inward; http://dx.doi.org/10.1007/s11908-996-0013-9; http://www.ncbi.nlm.nih.gov/pubmed/15023279; http://link.springer.com/10.1007/s11908-996-0013-9; https://dx.doi.org/10.1007/s11908-996-0013-9; https://link.springer.com/article/10.1007/s11908-996-0013-9; http://www.springerlink.com/index/10.1007/s11908-996-0013-9; http://www.springerlink.com/index/pdf/10.1007/s11908-996-0013-9
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know